Printer Friendly

Ampio Pharmaceuticals names two prominent scientists to Scientific Advisory Board.

M2 EQUITYBITES-December 4, 2013-Ampio Pharmaceuticals names two prominent scientists to Scientific Advisory Board


Ampio Pharmaceuticals Inc (NYSE MKT: AMPE), a development stage biopharmaceutical company, on Tuesday announced that Dr Pablo Rubinstein and Dr Edward Brody, two prominent scientists in the field of molecular biology and stem cell research, will be join its Scientific Advisory Board (SAB).

According to the company, it is currently advancing three drugs (Ampion, Optina and Zertane) and one diagnostic device (ORP) through clinical trials and commercialisation. New and clinically important, indications for these drugs are evident. Also, the company's drug portfolio also includes a large number of compounds that have already demonstrated in vitro activity as well as some in vivo efficacy in the treatment of inflammation and cancer. These compounds are protected by numerous patents that include composition of matter claims.

As a result, the company has decided to elevate its analytical ability to determine which clinical paths to pursue that will provide the most near term and cost effective increase to shareholder value and has formed a SAB, which a few carefully chosen scientists, after becoming familiar with the science of Ampio, have agreed to join.

These SAB members will support and augment Ampio's commercial progress by providing broad, as well as cutting edge, experience in the fields of stem cell research and molecular biology.

Also, this SAB will review the company's progress in research and clinical development as well as provide and evaluate new scientific perspectives alongside the company's management and scientists.

Rubinstein, MD, a surgeon and immunogeneticist by training, is the founder and director, of the National Cord Blood Programme at the New York Blood Centre (NYBC), where he developed the first public cord blood banking system. Reportedly, he has played a leading role in international cord blood transplantation in which the stem cells from the placental and umbilical cord blood of unrelated donors are used to treat, by transplantation, leukaemia, lymphoma and other neoplastic diseases of the blood. Earlier he has worked as investigator at the Lindsley F. Kimball Research Institute at the New York Blood Centre (NYBC) and eventually as director of the Fred H. Allen Jr. Laboratory of Immunogenetics. He has also served as clinical professor in the Pathology Department at Columbia University School of Medicine.

Dr Brody, MD, PhD, a physician, molecular biologist, biochemist and biophysicist by training, is the chief medical officer Emeritus of SomaLogic Inc and adjunct professor, Department of Molecular, Cellular and Developmental Biology; University of Colorado, Boulder. Dr Brody served as VP, Drug Discovery, NeXstar Pharmaceuticals and has been working in proteomics at SomaLogic since its inception in 2000.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 4, 2013
Previous Article:Conatus Pharmaceuticals receives emricasan orphan drug designation.
Next Article:Isis Pharmaceuticals receives USD2m milestone payment from GlaxoSmithKline.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters